BioLineRx (NASDAQ:BLRX) Given New $9.00 Price Target at HC Wainwright

BioLineRx (NASDAQ:BLRX) had its target price trimmed by HC Wainwright from $21.00 to $9.00 in a report issued on Monday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on shares of BioLineRx in a research note on Sunday. They set a “hold” rating for the company.

BioLineRx Stock Performance

Shares of BioLineRx stock opened at $0.27 on Monday. The stock has a market cap of $21.72 million, a price-to-earnings ratio of -0.60 and a beta of 1.48. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34. BioLineRx has a twelve month low of $0.25 and a twelve month high of $1.89. The company’s fifty day moving average is $0.48 and its 200 day moving average is $0.61.

Hedge Funds Weigh In On BioLineRx

Several large investors have recently added to or reduced their stakes in the business. Atria Investments Inc grew its position in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares in the last quarter. PVG Asset Management Corp bought a new position in shares of BioLineRx in the second quarter valued at approximately $70,000. Finally, CVI Holdings LLC purchased a new stake in shares of BioLineRx during the second quarter valued at approximately $462,000. Institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.